<p>Armistice Capital LLC 在第一季度购买了 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）的一项新股份，根据其最近向证券交易委员会（SEC）提交的 13F 文件。该基金购买了 2,988,000 股公司股票，价值约为 18,795,000 美元。在最近的报告期末，Armistice Capital LLC 持有 Trevi Therapeutics 约 2.99% 的股份。</p>
<p>其他一些机构投资者最近也买卖了 TRVI 的股票。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Trevi Therapeutics 的持仓增加了 40.7%。富国银行现在拥有 33,050 股公司股票，价值 136,000 美元，此前在上个季度又购买了 9,562 股。景顺（Invesco Ltd.）在第四季度将其在 Trevi Therapeutics 的持仓增加了 21.2%。景顺现在拥有 23,621 股公司股票，价值 97,000 美元，此前在上个季度又购买了 4,133 股。文艺复兴科技（Renaissance Technologies LLC）在第四季度将其在 Trevi Therapeutics 的持仓增加了 42.0%。文艺复兴科技现在拥有 100,400 股公司股票，价值 414,000 美元，此前在上个季度又购买了 29,700 股。雷蒙德·詹姆斯金融公司（Raymond James Financial Inc.）在第四季度购买了 Trevi Therapeutics 的一项新股份，价值 49,000 美元。最后，巴克莱银行（Barclays PLC）在第四季度将其在 Trevi Therapeutics 的持仓增加了 64.1%。巴克莱银行现在拥有 156,267 股公司股票，价值 643,000 美元，此前在上个季度又购买了 61,035 股。目前，95.76% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>一些分析师对该公司进行了评论。Oppenheimer 在 6 月 2 日的研究报告中重申了对 Trevi Therapeutics 股票的 “跑赢大盘” 评级。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究报告中将 Trevi Therapeutics 的目标价格从 29.00 美元下调至 27.00 美元，并对该股票设定了 “强力买入” 评级。Cantor Fitzgerald 在 7 月 1 日的报告中开始覆盖 Trevi Therapeutics。他们对该公司给予了 “增持” 评级，并设定了 25.00 美元的价格目标。Wall Street Zen 在 6 月 6 日的报告中将 Trevi Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，摩根士丹利在 8 月 21 日的报告中开始覆盖 Trevi Therapeutics。他们对该公司给予了 “增持” 评级，并设定了 18.00 美元的价格目标。两位股票研究分析师对该股票给予了强力买入评级，八位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，共识目标价格为 20.11 美元。</p>
<p><strong>查看我们关于 TRVI 的最新股票报告</strong></p>
<h2>Trevi Therapeutics 股票上涨 0.7%</h2>
<p>NASDAQ TRVI 在周五开盘价为 7.26 美元。该股票的市值为 8.8412 亿美元，市盈率为-17.29，贝塔值为 0.58。该公司的 50 日移动平均线为 6.92 美元，200 日移动平均线为 6.28 美元。Trevi Therapeutics, Inc.的 52 周最低价为 2.36 美元，52 周最高价为 8.78 美元。</p>
<p>Trevi Therapeutics（NASDAQ:TRVI - 获取免费报告）在 8 月 7 日星期四发布了其财报。该公司报告季度每股收益（EPS）为-0.09 美元，超出市场共识预期的-0.10 美元 0.01 美元。整体来看，分析师预计 Trevi Therapeutics, Inc.在当前年度将发布-0.49 美元的每股收益。</p>
<h2>关于 Trevi Therapeutics</h2>
<p>（免费报告）</p>
<p>Trevi Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于 Haduvio 疗法的开发和商业化，以治疗特发性肺纤维化（IPF）和难治性慢性咳嗽（RCC）等疾病，目标是中央和外周神经系统。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Trevi Therapeutics</li>
<li>哪些华尔街分析师最准确？</li>
<li>DICKS 运动用品公司股票在财报后下跌——值得买吗？</li>
<li>风险承受能力，适合所有人的方案并不存在</li>
<li>AI 引擎：康明斯的意外增长驱动因素</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>较小的工业公司正在经历快速增长：原因在这里</li>
</ul>
<p><strong>想看看其他对冲基金持有的 TRVI 吗？</strong> 访问 HoldingsChannel.com 以获取 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Trevi Therapeutics 吗？</h2>
<p>在考虑 Trevi Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Trevi Therapeutics 并不在名单上。</p>
<p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TRVI

<p>Armistice Capital LLC 在第一季度收购了 Trevi Therapeutics, Inc. (NASDAQ:TRVI) 的新股份，购买了 2,988,000 股，价值约为 1880 万美元，代表约 2.99% 的持股比例。其他机构投资者也增加了对 TRVI 的持股。分析师对该股票的评级不一，普遍目标价为 20.11 美元。Trevi Therapeutics 报告的季度每股收益为（0.09 美元），超出预期。该股票目前交易价格为 7.26 美元，市值为 8.8412 亿美元</p>

<p>Armistice Capital LLC purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,988,000 shares of the company's stock, valued at approximately $18,795,000. Armistice Capital LLC owned approximately 2.99% of Trevi Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Armistice Capital LLC 在第一季度购买了 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）的一项新股份，根据其最近向证券交易委员会（SEC）提交的 13F 文件。该基金购买了 2,988,000 股公司股票，价值约为 18,795,000 美元。在最近的报告期末，Armistice Capital LLC 持有 Trevi Therapeutics 约 2.99% 的股份。</p>
</div><p>A number of other institutional investors also recently bought and sold shares of TRVI. Wells Fargo &amp; Company MN boosted its position in Trevi Therapeutics by 40.7% during the fourth quarter. Wells Fargo &amp; Company MN now owns 33,050 shares of the company's stock worth $136,000 after purchasing an additional 9,562 shares in the last quarter. Invesco Ltd. boosted its position in Trevi Therapeutics by 21.2% during the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock worth $97,000 after purchasing an additional 4,133 shares in the last quarter. Renaissance Technologies LLC boosted its position in Trevi Therapeutics by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after purchasing an additional 29,700 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Trevi Therapeutics during the fourth quarter worth $49,000. Finally, Barclays PLC boosted its position in Trevi Therapeutics by 64.1% during the fourth quarter. Barclays PLC now owns 156,267 shares of the company's stock worth $643,000 after purchasing an additional 61,035 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了 TRVI 的股票。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Trevi Therapeutics 的持仓增加了 40.7%。富国银行现在拥有 33,050 股公司股票，价值 136,000 美元，此前在上个季度又购买了 9,562 股。景顺（Invesco Ltd.）在第四季度将其在 Trevi Therapeutics 的持仓增加了 21.2%。景顺现在拥有 23,621 股公司股票，价值 97,000 美元，此前在上个季度又购买了 4,133 股。文艺复兴科技（Renaissance Technologies LLC）在第四季度将其在 Trevi Therapeutics 的持仓增加了 42.0%。文艺复兴科技现在拥有 100,400 股公司股票，价值 414,000 美元，此前在上个季度又购买了 29,700 股。雷蒙德·詹姆斯金融公司（Raymond James Financial Inc.）在第四季度购买了 Trevi Therapeutics 的一项新股份，价值 49,000 美元。最后，巴克莱银行（Barclays PLC）在第四季度将其在 Trevi Therapeutics 的持仓增加了 64.1%。巴克莱银行现在拥有 156,267 股公司股票，价值 643,000 美元，此前在上个季度又购买了 61,035 股。目前，95.76% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Trevi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have commented on the company. Oppenheimer reiterated an &#34;outperform&#34; rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Raymond James Financial decreased their target price on Trevi Therapeutics from $29.00 to $27.00 and set a &#34;strong-buy&#34; rating on the stock in a research report on Friday, August 8th. Cantor Fitzgerald started coverage on Trevi Therapeutics in a report on Tuesday, July 1st. They issued an &#34;overweight&#34; rating and a $25.00 price target for the company. Wall Street Zen cut Trevi Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Friday, June 6th. Finally, Morgan Stanley started coverage on Trevi Therapeutics in a report on Thursday, August 21st. They issued an &#34;overweight&#34; rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and a consensus target price of $20.11.</p>
<div class="lb-trans"><p>一些分析师对该公司进行了评论。Oppenheimer 在 6 月 2 日的研究报告中重申了对 Trevi Therapeutics 股票的 “跑赢大盘” 评级。雷蒙德·詹姆斯金融公司在 8 月 8 日的研究报告中将 Trevi Therapeutics 的目标价格从 29.00 美元下调至 27.00 美元，并对该股票设定了 “强力买入” 评级。Cantor Fitzgerald 在 7 月 1 日的报告中开始覆盖 Trevi Therapeutics。他们对该公司给予了 “增持” 评级，并设定了 25.00 美元的价格目标。Wall Street Zen 在 6 月 6 日的报告中将 Trevi Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，摩根士丹利在 8 月 21 日的报告中开始覆盖 Trevi Therapeutics。他们对该公司给予了 “增持” 评级，并设定了 18.00 美元的价格目标。两位股票研究分析师对该股票给予了强力买入评级，八位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，共识目标价格为 20.11 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on TRVI</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TRVI 的最新股票报告</strong></p>
</div><h2>Trevi Therapeutics Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 股票上涨 0.7%</h2>
</div><p>NASDAQ TRVI opened at $7.26 on Friday. The stock has a market cap of $884.12 million, a price-to-earnings ratio of -17.29 and a beta of 0.58. The business has a fifty day moving average of $6.92 and a 200-day moving average of $6.28. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $8.78.</p>
<div class="lb-trans"><p>NASDAQ TRVI 在周五开盘价为 7.26 美元。该股票的市值为 8.8412 亿美元，市盈率为-17.29，贝塔值为 0.58。该公司的 50 日移动平均线为 6.92 美元，200 日移动平均线为 6.28 美元。Trevi Therapeutics, Inc.的 52 周最低价为 2.36 美元，52 周最高价为 8.78 美元。</p>
</div><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.</p>
<div class="lb-trans"><p>Trevi Therapeutics（NASDAQ:TRVI - 获取免费报告）在 8 月 7 日星期四发布了其财报。该公司报告季度每股收益（EPS）为-0.09 美元，超出市场共识预期的-0.10 美元 0.01 美元。整体来看，分析师预计 Trevi Therapeutics, Inc.在当前年度将发布-0.49 美元的每股收益。</p>
</div><h2>About Trevi Therapeutics</h2>
<div class="lb-trans"><h2>关于 Trevi Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于 Haduvio 疗法的开发和商业化，以治疗特发性肺纤维化（IPF）和难治性慢性咳嗽（RCC）等疾病，目标是中央和外周神经系统。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Trevi Therapeutics</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Engines to AI: Cummins’ Surprising Growth Driver</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Trevi Therapeutics</li>
<li>哪些华尔街分析师最准确？</li>
<li>DICKS 运动用品公司股票在财报后下跌——值得买吗？</li>
<li>风险承受能力，适合所有人的方案并不存在</li>
<li>AI 引擎：康明斯的意外增长驱动因素</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>较小的工业公司正在经历快速增长：原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TRVI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 TRVI 吗？</strong> 访问 HoldingsChannel.com 以获取 Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Trevi Therapeutics 吗？</h2>
</div><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Trevi Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Trevi Therapeutics 并不在名单上。</p>
</div><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Armistice Capital LLC 购入了 Trevi Therapeutics, Inc.的新股权 $TRVI